On July 23, Roche announced its performance report for the first half of 2020. Total revenue was 29.3 billion Swiss francs, down 4% year-on-year, of which pharmaceutical business revenue was 23.2 billion Swiss francs, down 4% year-on-year.
Roche was severely affected by COVID-19 in 2020Q2, and sales revenue experienced negative growth for the first time, falling by 4%. Especially in May, sales revenue fell seriously15.
Sales of Roche’s troika Avastin (bevacizumab), Rituxan (rituximab) and Herceptin (trastuzumab) have all fallen sharply due to the impact of biosimilars. . Among them, Avastin's global sales in the first half of 2020 were 2.845 billion Swiss francs, a year-on-year decrease of 18%, and the US market sales dropped significantly by 33%; Rituxan's global sales were 2.440 billion Swiss francs, a year-on-year decrease of 23%, and the European market dropped 34%; Herceptin's global sales were 2.440 billion Swiss francs, a year-on-year decrease of 23%. 2.20 billion Swiss francs, a year-on-year decrease of 28%, and the US market decreased by 42%.
Top 20 Roche drug sales in 2020H1 (billion Swiss francs)
On the other hand, Roche’s newly approved products have performed well in recent years, and Perjeta (Pertuzumab) has performed well. Half-year sales reached 1.941 billion Swiss francs, a year-on-year increase of 17%; the PD-L1 drug Tecentriq was driven by indications for extensive-stage small cell lung cancer and triple-negative breast cancer, with sales reaching 1.297 billion Swiss francs, an increase of 74%; the multiple sclerosis drug Ocrevus and hemophilia drug Hemlibra, despite being severely impacted by COVID-19, still achieved growth rates of 25 and 94, respectively.
Although Actemra (tocilizumab) has not been approved for COVID-19 indications, it has been included in diagnosis and treatment guidelines in some countries. Sales in the first half of the year were 1.461 billion Swiss francs, an increase of 36%.
Send Roche to the official account to get Roche’s 2020 first half financial report PPT
Click on “Looking” to be accompanied by good articles